Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence

Article Respiratory System

Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial

Manuel Taboada et al.

Summary: High-dose dexamethasone reduces clinical worsening in COVID-19 patients receiving oxygen therapy within 11 days after randomization.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Critical Care Medicine

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

Anders Granholm et al.

Summary: The study showed that in patients with COVID-19 and severe hypoxaemia, daily use of dexamethasone 12 mg compared to 6 mg had high probabilities of benefit and low probabilities of clinically important harm in all outcomes up to 90 days.

INTENSIVE CARE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

Nicole Wolter et al.

Summary: According to data analysis from South Africa, individuals infected with the omicron variant have a lower likelihood of hospitalization compared to those infected with non-omicron variants. Furthermore, individuals infected with the omicron variant have a lower odds of severe disease compared to individuals infected with the earlier delta variant.

LANCET (2022)

Add to Collection

Article Pharmacology & Pharmacy

Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial

Negar Toroghi et al.

Summary: This study compared the efficacy and safety of different doses of dexamethasone in treating patients with moderate to severe COVID-19. The results showed that low-dose dexamethasone had better clinical response and longer survival compared to high-dose dexamethasone, with some adverse effects slightly higher in the intermediate and high-dose groups than in the low-dose group.

PHARMACOLOGICAL REPORTS (2022)

Add to Collection

Article Critical Care Medicine

High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial

Luis Patricio Maskin et al.

Summary: Among patients with ARDS caused by COVID-19, the use of higher doses of dexamethasone compared with the recommended low-dose treatment did not show an increase in ventilator-free days. However, the higher dose significantly improved the time required to liberate them from the ventilator.

JOURNAL OF INTENSIVE CARE MEDICINE (2022)

Add to Collection

Review Infectious Diseases

The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries

Martin Hoenigl et al.

Summary: Reports of COVID-19-associated mucormycosis, particularly among patients with uncontrolled diabetes, have been increasing since early 2021. Most patients with COVID-19-associated mucormycosis have uncontrolled diabetes and receive systemic corticosteroid treatment, and rhino-orbital cerebral mucormycosis is the most common disease. COVID-19-associated mucormycosis is associated with high mortality and a significant proportion of survivors experience life-changing morbidities.

LANCET MICROBE (2022)

Add to Collection

Letter Medicine, General & Internal

Geographical Representation of Low- and Middle-Income Countries in Randomized Clinical Trials for COVID-19

Mahesh Ramanan et al.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Infectious Diseases

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Oliver J. Watson et al.

Summary: A study quantified the global impact of the first year of COVID-19 vaccination programs, finding that the vaccination has substantially altered the course of the pandemic, saving tens of millions of lives globally. However, inadequate access to vaccines in low-income countries has limited the impact, reinforcing the need for global vaccine equity and coverage.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Review Medicine, General & Internal

Inhaled corticosteroids for the treatment of COVID-19

Mirko Griesel et al.

Summary: This study assessed the effectiveness and safety of inhaled corticosteroids in the treatment of COVID-19. The findings suggest that inhaled corticosteroids may reduce the risk of hospital admission or death and improve symptom resolution in people with mild COVID-19. However, there is low certainty evidence regarding the impact on mortality, serious adverse events, and infections. Further research is needed to determine the effects of inhaled corticosteroids on these outcomes.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2022)

Add to Collection

Article Critical Care Medicine

Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial

Yewande E. Odeyemi et al.

CRITICAL CARE (2022)

Add to Collection

Article Infectious Diseases

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Oliver J. Watson et al.

Summary: The study estimated that COVID-19 vaccination has prevented millions of deaths globally between December 8, 2020, and December 8, 2021. Achieving the vaccination coverage targets set by COVAX and WHO could have prevented even more deaths. However, limited access to vaccines in low-income countries has hindered the impact, highlighting the importance of global vaccine equity.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial

Christiane Maria Prado Jeronimo et al.

Summary: This study evaluated the efficacy of methylprednisolone (MP) among hospitalized patients with suspected COVID-19 and found that a short course of MP did not reduce mortality in the overall population. However, patients over 60 years old in the MP group had a lower mortality rate, suggesting potential benefits for this age group.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Review Endocrinology & Metabolism

Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action

Imad M. El-Kebbi et al.

Summary: Type 2 diabetes has a high prevalence in the Middle East and North Africa region, attributed to obesity, lack of physical activity, urbanization, and poor dietary habits. Efforts to control diabetes and its complications are complicated by political instability, conflicts, and the recent COVID-19 pandemic.

WORLD JOURNAL OF DIABETES (2021)

Add to Collection

Article

The role and place of glucocorticosteroids in treatment of COVID-19 pneumonia without hypoxemia

V. V. Salukhov et al.

Meditsinskiy Sovet (2021)

Add to Collection

Meeting Abstract Critical Care Medicine

HIGH-DOSE VS LOW-DOSE DEXAMETHASONE IN PATIENTS WITH COVID-19 IN A TERTIARY HOSPITAL IN WESTERN HONDURAS

Eleazar Montalvan et al.

CHEST (2021)

Add to Collection

Article Infectious Diseases

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021

Lin T. Brandal et al.

Summary: In the Omicron SARS-CoV-2 outbreak in Oslo, Norway, most infected individuals were aged 30-50, 96% were vaccinated, with an attack rate of 74%, but none required hospitalization.

EUROSURVEILLANCE (2021)

Add to Collection

Article Respiratory System

Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial

Xiao Tang et al.

Summary: The study did not find a benefit of short-term early use of corticosteroids in treating patients with COVID-19 pneumonia in terms of clinical deterioration, but it may prolong the shedding of the virus. The number of immune cells was significantly reduced in the treatment group.

RESPIRATION (2021)

Add to Collection

Letter Medicine, Research & Experimental

Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial

Inigo Les Bujanda et al.

Summary: The study aims to assess the effectiveness and safety of glucocorticoid infusion pulse therapy for COVID-19 pneumonia patients with elevated inflammatory biomarkers. It is a randomized controlled trial conducted in two hospitals in Spain. Eligible participants are patients admitted to hospital due to COVID-19 pneumonia who meet the inclusion criteria specified in the study protocol.

TRIALS (2021)

Add to Collection

Article Medicine, General & Internal

Sex and age differences in COVID-19 mortality in Europe

Linda Juel Ahrenfeldt et al.

Summary: The study found that men had a higher relative risk of dying from COVID-19 compared to women in almost all age groups across ten European regions, but this sex difference decreased with age, with the smallest difference observed in the 80+ age group. Despite variations in data collection and time coverage, the overall pattern of sex differences in COVID-19 mortality in Europe was similar.

WIENER KLINISCHE WOCHENSCHRIFT (2021)

Add to Collection

Article Medicine, General & Internal

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial

Marie W. Munch et al.

Summary: In patients with COVID-19 and severe hypoxemia, the use of 12 mg/d of dexamethasone compared to 6 mg/d did not lead to a statistically significant difference in the number of days alive without life support at 28 days. The study may have lacked the power to detect a significant effect.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Anesthesiology

Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan

Marie Warrer Munch et al.

Summary: The COVID STEROID 2 trial aims to evaluate the benefits and harms of using higher (12 mg) vs. lower (6 mg) doses of dexamethasone in patients with COVID-19. The study plans to recruit 1,000 patients, with the primary outcome being the number of days alive without life support at day 28. This will help determine the optimal dosage of systemic corticosteroids for COVID-19 patients with severe hypoxia.

ACTA ANAESTHESIOLOGICA SCANDINAVICA (2021)

Add to Collection

Article Otorhinolaryngology

Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial

Abdelrahman Ahmed Abdelalim et al.

Summary: The study found that using mometasone furoate nasal spray as a topical corticosteroid for post COVID-19 anosmia did not offer significant benefits over olfactory training, with no statistical differences in treatment outcomes and recovery rates.

AMERICAN JOURNAL OF OTOLARYNGOLOGY (2021)

Add to Collection

Article Anesthesiology

Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials

Laura Pasin et al.

Summary: The efficacy and safety of corticosteroids in patients with COVID-19 are still debated. Recent trials have shown that corticosteroids may be beneficial for severely ill patients but should be discouraged in those not requiring oxygen therapy. Further clinical trials are needed before widespread implementation of this treatment.

JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2021)

Add to Collection

Article Medicine, General & Internal

Methylprednisolone in adults hospitalized with COVID-19 pneumonia An open-label randomized trial (GLUCOCOVID)

Luis Corral-Gudino et al.

Summary: This study aimed to investigate whether methylprednisolone improves outcomes in severe COVID-19 patients. Results showed that patients on methylprednisolone had a significantly lower risk of experiencing the composite endpoint in the per protocol analysis. However, the planned sample size was not achieved, cautioning interpretation of the results.

WIENER KLINISCHE WOCHENSCHRIFT (2021)

Add to Collection

Review Infectious Diseases

COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India

Jesil Mathew Aranjani et al.

Summary: The second wave of COVID-19 in early 2021 has caused devastating chaos in India, with a sudden surge of mucormycosis in COVID-19 patients presenting a major challenge. Diabetic patients are more susceptible to this fungal infection, and treatment strategies primarily involve surgical debridement and antifungal therapy.

PLOS NEGLECTED TROPICAL DISEASES (2021)

Add to Collection

Article Pharmacology & Pharmacy

No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial

Hamidreza Jamaati et al.

Summary: The study evaluated the clinical effects of dexamethasone administration in patients with mild to moderate ARDS due to COVID-19. Results showed no significant clinical benefit of corticosteroid administration in these patients.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Article Infectious Diseases

Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study

Charlotte Thibeault et al.

Summary: Adequate patient allocation in healthcare systems is crucial for resource management. This study identified risk factors for invasive mechanical ventilation (IMV) in COVID-19 patients, showing shorter symptom duration and a history of hypertension as associated factors. Patients on IMV had different viral kinetics and longer hospitalization compared to non-IMV patients.

INFECTION (2021)

Add to Collection

Review Critical Care Medicine

Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis

Dipayan Chaudhuri et al.

Summary: The study found that corticosteroids may reduce mortality in patients with ARDS, with a longer course of treatment showing better results. The effect of corticosteroids was consistent across patients with COVID-19 and non-COVID-19 ARDS, different types and dosages of corticosteroids.

INTENSIVE CARE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Short-Course of Methylprednisolone Improves Respiratory Functional Parameters After 120 Days in Hospitalized COVID-19 Patients (Metcovid Trial): A Randomized Clinical Trial

Camila Miriam Suemi Sato Barros et al.

Summary: The study found that using corticosteroids for at least 5 days in severe COVID-19 patients may help improve lung function and reduce long-term pulmonary restrictive functions caused by fibrosis.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform

Rohini Mathur et al.

Summary: The study found that some minority ethnic populations in England have higher risks of testing positive for SARS-CoV-2 and experiencing adverse COVID-19 outcomes compared to the White population, even after adjusting for sociodemographic, clinical, and household characteristics.

LANCET (2021)

Add to Collection

Editorial Material Medicine, General & Internal

COVID-19 and disparities affecting ethnic minorities

Daniel R. Morales et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab

Alaa Rashad et al.

Summary: The study compared the short-term survival of critically ill COVID-19 patients treated with tocilizumab (TCZ) and dexamethasone, finding that patients in the dexamethasone group had better survival outcomes. Considering treatment choice and specific risk factors for each patient is crucial in managing severe COVID-19 cases.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences

Climate and the spread of COVID-19

Simiao Chen et al.

Summary: The visual inspection of global maps indicates that COVID-19 is less prevalent in countries closer to the equator due to higher temperatures and humidity. Regression analysis shows that countries closer to the equator can expect fewer cases per million inhabitants, with a decline in cases expected during summer. However, this does not suggest that the virus will vanish in summer, but rather higher temperatures and UV radiation may support public health measures to contain the virus.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Anesthesiology

Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trial

Marie Warrer Munch et al.

Summary: The study aimed to assess the effects of low-dose hydrocortisone on patients with severe hypoxia due to COVID-19, but was terminated early with only 3% of the planned sample size enrolled, leading to imprecise estimates of benefits and harms.

ACTA ANAESTHESIOLOGICA SCANDINAVICA (2021)

Add to Collection

Article

A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease

Praveen B Gautam et al.

Asian Journal of Medical Sciences (2021)

Add to Collection

Article Multidisciplinary Sciences

The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19

Ann M. Navar et al.

Summary: Among hospitalized COVID-19 patients in the United States, there are racial and ethnic disparities in mortality rates, with Black adults showing higher mortality rates due to a higher burden of comorbidities. In contrast, Hispanic patients exhibit lower mortality rates even after adjusting for various demographic and clinical factors.

PLOS ONE (2021)

Add to Collection

Article Immunology

Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

Thais G. Moreira et al.

Summary: The study found that nasal Foralumab treatment led to reduction in serum IL-6 and C-reactive protein levels, as well as faster clearance of lung infiltrates in COVID-19 patients. The treatment was well-tolerated with no severe adverse events reported. Further studies are needed to explore the potential benefits of Foralumab in managing immune hyperactivity and lung involvement in COVID-19.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial

Naveen B. Naik et al.

Summary: The study found that in patients with moderate to severe COVID-19 ARDS, high-dose dexamethasone (HDD) had lower VFDs compared to tocilizumab (TCZ), and the HDD group had higher 28-day mortality and incidence of adverse events. Therefore, HDD is not recommended for mitigating the cytokine storm in moderate to severe COVID-19 ARDS, and TCZ appears to be a better and safer alternative.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Ethnicity and acute hospital admissions: Multi-center analysis of routine hospital data

Yize I. Wan et al.

Summary: This study examined the impact of ethnic and social disparities on acute healthcare outcomes, revealing that non-white patients were younger and more likely to be admitted to the hospital, with a lower mortality risk compared to white patients. However, deprivation was associated with increased mortality in all ethnic groups.

ECLINICALMEDICINE (2021)

Add to Collection

Article Respiratory System

The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial

Mostafa Ghanei et al.

Summary: The study showed that the low-dose prednisolone regimen was superior to other treatments in shortening the hospital stay of patients with moderate to severe COVID-19. The steroid-sparing effect may be beneficial in enhancing the effectiveness of corticosteroids for diabetic patients by reducing the dosage.

RESPIRATORY RESEARCH (2021)

Add to Collection

Review Medicine, General & Internal

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Vanessa Piechotta et al.

Summary: Convalescent plasma and hyperimmune immunoglobulin are being investigated as potential therapies for COVID-19, with a living systematic review approach being used to assess their effectiveness and safety. The current evidence suggests that convalescent plasma does not reduce all-cause mortality or significantly improve clinical outcomes for individuals with moderate to severe disease, but its impact on other outcomes remains uncertain. Further ongoing studies are needed to determine the full potential of these interventions.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

Add to Collection

Article Medicine, Research & Experimental

Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol

X. Solanich et al.

Summary: Methylprednisolone and tacrolimus may be a beneficial combination for treating severe COVID-19 patients with pulmonary failure and systemic hyperinflammatory syndrome. The rationale for their use lies in the fast effect of methylprednisolone and the ability of tacrolimus to inhibit both CoV-2 replication and the secondary cytokine storm. Additionally, both drugs are cost-effective and can be produced on a large scale, potentially benefitting a large number of patients worldwide.

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2021)

Add to Collection

Review Medicine, General & Internal

Remdesivir for the treatment of COVID-19

Kelly Ansems et al.

Summary: The results from five randomized controlled trials suggest that remdesivir has little or no effect on all-cause mortality at up to 28 days among hospitalized adults with SARS-CoV-2 infection. Uncertainty remains regarding the effects of remdesivir on clinical improvement and worsening. Future studies should provide more data to draw more reliable conclusions about the potential benefits and harms of remdesivir.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

Add to Collection

Review Medicine, General & Internal

Colchicine for the treatment of COVID-19

Agata Mikolajewska et al.

Summary: The use of colchicine in hospitalized individuals with moderate to severe COVID-19 may not significantly affect mortality or clinical progression compared to placebo or standard care alone. However, colchicine may slightly reduce hospital admissions or deaths within 28 days in individuals with asymptomatic or mild COVID-19 infection, with uncertain evidence regarding serious adverse events. Future studies are needed to further explore the impact of colchicine on different populations and outcomes.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

Add to Collection

Article Health Care Sciences & Services

GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles

Nicole Skoetz et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)

Add to Collection

Review Health Care Sciences & Services

GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions

Nancy Santesso et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

Add to Collection

Editorial Material Oncology

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Wenhua Liang et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Stephen A. Lauer et al.

ANNALS OF INTERNAL MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial

Yuan-Yuan Qin et al.

CHINESE MEDICAL JOURNAL (2020)

Add to Collection

Article Critical Care Medicine

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

Jesus Villar et al.

LANCET RESPIRATORY MEDICINE (2020)

Add to Collection

Review Health Care Sciences & Services

An overview of platform trials with a checklist for clinical readers

Jay J. H. Park et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)

Add to Collection

Article Anesthesiology

Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan

Marie Warrer Petersen et al.

ACTA ANAESTHESIOLOGICA SCANDINAVICA (2020)

Add to Collection

Review Medicine, General & Internal

Prevalence of Asymptomatic SARS-CoV-2 Infection A Narrative Review

Daniel P. Oran et al.

ANNALS OF INTERNAL MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Jonas Schulte-Schrepping et al.

CELL (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study

Pedro Baqui et al.

LANCET GLOBAL HEALTH (2020)

Add to Collection

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

Add to Collection

Article Respiratory System

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

Maryam Edalatifard et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Add to Collection

Article Medicine, Research & Experimental

Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial

Miriam Saiz-Rodriguez et al.

TRIALS (2020)

Add to Collection

Letter Medicine, Research & Experimental

Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial

Nafiseh Abdolahi et al.

TRIALS (2020)

Add to Collection

Article Mathematical & Computational Biology

Embedding a COVID-19 Group Sequential Clinical Trial Within an Ongoing Trial: Lessons From an Unusual Experience

Pierre-Francois Dequin et al.

STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2020)

Add to Collection

Review Medicine, General & Internal

Drug treatments for covid-19: living systematic review and network meta-analysis

Reed A. C. Siemieniuk et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial

Pierre-Francois Dequin et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

Bruno M. Tomazini et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Derek C. Angus et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Letter Medicine, Research & Experimental

Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial

Stefano Busani et al.

TRIALS (2020)

Add to Collection

Article Medicine, Research & Experimental

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

Luis Patricio Maskin et al.

TRIALS (2020)

Add to Collection

Review Endocrinology & Metabolism

Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes

Janine Alessi et al.

DIABETOLOGY & METABOLIC SYNDROME (2020)

Add to Collection

Article Medicine, General & Internal

Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis

Diana Buitrago-Garcia et al.

PLOS MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease

Thomas Struyf et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)

Add to Collection

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Review Microbiology

Global Epidemiology of Mucormycosis

Hariprasath Prakash et al.

JOURNAL OF FUNGI (2019)

Add to Collection

Review Critical Care Medicine

Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis

Bram Rochwerg et al.

CRITICAL CARE MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study

Akbar K. Waljee et al.

BMJ-BRITISH MEDICAL JOURNAL (2017)

Add to Collection

Article Medicine, General & Internal

Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study

Akbar K. Waljee et al.

BMJ-BRITISH MEDICAL JOURNAL (2017)

Add to Collection

Review Medicine, General & Internal

Rayyan-a web and mobile app for systematic reviews

Mourad Ouzzani et al.

SYSTEMATIC REVIEWS (2016)

Add to Collection

Article Critical Care Medicine

Corticosteroids and Transition to Delirium in Patients With Acute Lung Injury

Matthew P. Schreiber et al.

CRITICAL CARE MEDICINE (2014)

Add to Collection

Article Endocrinology & Metabolism

Comorbid Diabetes and COPD Impact of corticosteroid use on diabetes complications

Gillian E. Caughey et al.

DIABETES CARE (2013)

Add to Collection

Review Medicine, General & Internal

PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity

Vivian Welch et al.

PLOS MEDICINE (2012)

Add to Collection

Review Endocrinology & Metabolism

Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function

Matthew D. Taves et al.

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2011)

Add to Collection

Article Health Care Sciences & Services

How to handle mortality when investigating length of hospital stay and time to clinical stability

Guy N. Brock et al.

BMC MEDICAL RESEARCH METHODOLOGY (2011)

Add to Collection

Review Health Care Sciences & Services

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)

Add to Collection

Article Medicine, Research & Experimental

Practical methods for incorporating summary time-to-event data into meta-analysis

Jayne F. Tierney et al.

TRIALS (2007)

Add to Collection

Review Immunology

Immunosenescence: emerging challenges for an ageing population

Danielle Aw et al.

IMMUNOLOGY (2007)

Add to Collection

Review Pharmacology & Pharmacy

How corticosteroids control inflammation: Quintiles prize lecture 2005

Peter J. Barnes

BRITISH JOURNAL OF PHARMACOLOGY (2006)

Add to Collection

Review Medicine, General & Internal

Antiinflammatory action of glucocorticoids - New mechanisms for old drugs

T Rhen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Add to Collection

Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence

Related references

Export Citation

Share Paper